Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

September 30, 2014

Conditions
Diabetic Nephropathy
Interventions
DRUG

Probucol 250mg/day

Probucol 250mg + Placebo

DRUG

Probucol 500mg/day

Probucol 500mg + Placebo

DRUG

Placebo

Probucol matching placebo

Trial Locations (16)

Unknown

The Catholic university of Korea, Bucheon St. Mary's Hospital, Bucheon-si

Kyungpook National University, Daegu

Yeungnam University Medical Center, Daegu

Gil Hospital, Incheon

Inha University Hospital, Incheon

Chonbuk national University Hospital, Jeonju

Eulji Hospital, Seoul

Kangbuk Samsung Hospital, Seoul

Kangnam Sacred Hospital, Seoul

Korea University Guro Hospital, Seoul

Kyunghee Univ Hospital at Kangdong, Seoul

Samsumg Medical Center, Seoul

Severance Hospital, Seoul

Seoul National University Bundang Hospital, SungNam

St. Vincent Hospital, Suwon

UIJEONGBU ST. MARY's HOSPITAL, Uijeongbu-si

All Listed Sponsors
lead

Korea Otsuka Pharmaceutical Co., Ltd.

INDUSTRY